Description:
<p><b>Fenbendazole</b> — a synthetic benzimidazole carbamate anthelmintic used to treat gastrointestinal parasites in veterinary medicine. It is formally classified as a veterinary antiparasitic drug. Its antiparasitic action involves binding parasite β-tubulin and disrupting microtubule-dependent processes. In experimental cancer systems, fenbendazole acts as a moderate microtubule-destabilizing agent and also perturbs glucose utilization, proteasomal protein degradation, endoplasmic-reticulum homeostasis, mitochondrial function, and stress-response pathways. Fenbendazole is not approved as a human drug or cancer therapy, and veterinary formulations are not manufactured or quality-controlled for human use.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Disruption of β-tubulin polymerization and microtubule dynamics, producing mitotic dysfunction and proliferation arrest.</li>
<li>Impairment of ubiquitin-proteasome function, causing accumulation of misfolded proteins, endoplasmic-reticulum stress, and pro-death signaling.</li>
<li>Inhibition of glucose uptake and glycolytic energy production, increasing metabolic stress in glycolysis-dependent cancer cells.</li>
<li>Induction of mitochondrial dysfunction, mitochondrial membrane-potential loss, cytochrome-c release, and intrinsic apoptosis.</li>
<li>Activation or stabilization of p53 signaling through MDM2 and MDMX suppression and mitochondrial p53 translocation in responsive models.</li>
<li>ROS elevation and oxidative-stress amplification secondary to proteotoxic, metabolic, and mitochondrial stress.</li>
<li>Activation of stress-associated MAPK and ER-stress pathways, including p38 MAPK, ATF3, IRE1, GRP78, CHOP, and NOXA in selected models.</li>
<li>Suppression of HK2-dependent glycolysis and induction of inflammatory pyroptotic cell death in selected breast-cancer models.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Fenbendazole has very low aqueous solubility and inconsistent gastrointestinal absorption. It undergoes extensive first-pass oxidation to the pharmacologically active sulfoxide metabolite oxfendazole and subsequently to fenbendazole sulfone. Food, formulation, species, and metabolic conditions can substantially alter exposure. Direct human fenbendazole PK and repeated-dose safety data are inadequate; available human benzimidazole PK work largely concerns oxfendazole rather than intentional fenbendazole treatment.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer experiments use approximately low-to-moderate micromolar fenbendazole concentrations, commonly around 0.5–10 µM. Whether these concentrations can be maintained safely in human tumors after oral veterinary-product administration is unknown. Poor solubility, rapid metabolism, variable absorption, and uncertain tissue penetration are major translational constraints. Activity observed after direct culture exposure should not be interpreted as evidence that ordinary oral dosing produces equivalent systemic exposure.</p>
<p><b>Clinical evidence status:</b> Preclinical only for efficacy. Evidence consists primarily of cancer-cell experiments and rodent or veterinary tumor models. Published self-administration case reports and small case series cannot establish benefit because patients generally received concurrent surgery, chemotherapy, immunotherapy, radiation, or other agents. No completed randomized controlled trial has demonstrated anticancer efficacy, no validated human oncology dose has been established, and fenbendazole is not approved by the FDA, Health Canada, or other major regulators for human cancer treatment. Clinically important hepatocellular drug-induced liver injury has been reported after self-administration, including biopsy-confirmed severe cases.</p>
<br>
-Fenbendazole works by binding to tubulin, a protein that is important in cell division, which may theoretically affect rapidly dividing cells like cancer cells. However, this mechanism is not selective for cancer cells and could affect normal cells as well.<br>
<br>
-Albendazole and fenbendazole, two approved and commonly used benzimidazole anthelmintics<br>
<br>
-Panacure C :1g granules (or 222mg Fenbendazole, for small dogs)<br>
<br>
<h3>Fenbendazole Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>β-Tubulin and microtubule dynamics</td>
<td>↓</td>
<td>↓ (proliferating cells)</td>
<td>P</td>
<td>Microtubule destabilization</td>
<td>Direct class-associated mechanism. Fenbendazole appears to be a moderate rather than highly potent mammalian microtubule destabilizer.</td>
</tr>
<tr>
<td>2</td>
<td>Mitotic progression and proliferation</td>
<td>↓</td>
<td>↓ (proliferation-dependent)</td>
<td>R/G</td>
<td>Mitotic dysfunction and growth arrest</td>
<td>Loss of spindle integrity and impaired chromosome segregation can reduce clonogenic survival. Selectivity is incomplete.</td>
</tr>
<tr>
<td>3</td>
<td>Ubiquitin-proteasome pathway</td>
<td>↓</td>
<td>↔ / ↓ (dose-dependent)</td>
<td>R</td>
<td>Proteotoxic stress</td>
<td>Proteasomal impairment and accumulation of ubiquitinated proteins were demonstrated in lung-cancer models and may be mechanistically important beyond tubulin disruption.</td>
</tr>
<tr>
<td>4</td>
<td>Endoplasmic-reticulum stress response</td>
<td>↑</td>
<td>↔ / ↑ (high concentration only)</td>
<td>R/G</td>
<td>IRE1, GRP78, ATF3 and CHOP activation</td>
<td>Persistent unfolded-protein stress promotes NOXA induction and apoptosis. Evidence is model-dependent.</td>
</tr>
<tr>
<td>5</td>
<td>Glucose uptake and glycolysis</td>
<td>↓</td>
<td>↔ / ↓ (dose-dependent)</td>
<td>R</td>
<td>Reduced glycolytic energy production</td>
<td>Reduced glucose uptake and glycolytic output are reported in several models. HK2 downregulation has been implicated in breast-cancer cells.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondrial membrane potential</td>
<td>↓</td>
<td>↔ / ↓ (high concentration only)</td>
<td>R</td>
<td>Mitochondrial dysfunction</td>
<td>Membrane-potential loss and cytochrome-c release link metabolic and proteotoxic stress to intrinsic apoptosis.</td>
</tr>
<tr>
<td>7</td>
<td>Intrinsic apoptosis</td>
<td>↑</td>
<td>↔ / ↑ (proliferation-dependent)</td>
<td>G</td>
<td>Caspase-associated cell death</td>
<td>Associated with cytochrome-c release, NOXA induction, and mitochondrial p53 activity. The contribution of individual pathways varies by cell type.</td>
</tr>
<tr>
<td>8</td>
<td>MDM2 and MDMX p53 axis</td>
<td>p53 ↑</td>
<td>↔</td>
<td>R/G</td>
<td>Tumor-suppressor activation</td>
<td>MDM2 and MDMX suppression can stabilize p53. Responses depend on intact p53 signaling and may be weak or absent in TP53-mutant tumors.</td>
</tr>
<tr>
<td>9</td>
<td>Mitochondrial p53 translocation</td>
<td>↑ (model-dependent)</td>
<td>↔</td>
<td>R</td>
<td>Transcription-independent apoptosis</td>
<td>Reported in human cancer-cell models and may connect microtubule disruption with mitochondrial permeabilization.</td>
</tr>
<tr>
<td>10</td>
<td>ROS and oxidative stress</td>
<td>↑</td>
<td>↔ / ↑ (high concentration only)</td>
<td>P/R</td>
<td>Oxidative-stress amplification</td>
<td>ROS elevation is reproducible in selected models but is generally secondary to proteasome, mitochondrial, or metabolic disruption rather than the initiating target.</td>
</tr>
<tr>
<td>11</td>
<td>NRF2 antioxidant response</td>
<td>↔ (context-dependent)</td>
<td>↔</td>
<td>R/G</td>
<td>Uncertain adaptive response</td>
<td>No consistent evidence supports NRF2 as a direct fenbendazole target. NRF2 modulation should not be assigned a fixed direction without product-specific experimental evidence.</td>
</tr>
<tr>
<td>12</td>
<td>MEK3 and MEK6 p38 MAPK stress signaling</td>
<td>↑</td>
<td>↔ / ↑ (high concentration only)</td>
<td>R</td>
<td>Stress-mediated growth inhibition</td>
<td>Observed in HeLa-cell experiments involving oxidative stress and altered energy metabolism.</td>
</tr>
<tr>
<td>13</td>
<td>HK2 glycolysis and pyroptosis</td>
<td>HK2 ↓ and pyroptosis ↑</td>
<td>↔</td>
<td>R/G</td>
<td>Inflammatory lytic cell death</td>
<td>Recent breast-cancer evidence identifies an HK2-linked pyroptosis mechanism. It is not yet established as a general mechanism across tumor types.</td>
</tr>
<tr>
<td>14</td>
<td>HIF-1α hypoxia adaptation</td>
<td>↓ (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Reduced hypoxic adaptation</td>
<td>Limited evidence suggests HIF-1α reduction in specific experimental contexts. This is a secondary and insufficiently generalized mechanism.</td>
</tr>
<tr>
<td>15</td>
<td>Chemosensitization</td>
<td>↑ / ↔ (combination-dependent)</td>
<td>Unknown</td>
<td>G</td>
<td>Potential additive or synergistic cytotoxicity</td>
<td>Preclinical combinations have been investigated, but interaction direction varies by drug and model. Clinical safety and efficacy are unestablished.</td>
</tr>
<tr>
<td>16</td>
<td>Clinical Translation Constraint</td>
<td>↓</td>
<td>↓</td>
<td>G</td>
<td>Uncertain exposure and dose-limiting toxicity</td>
<td>Poor solubility, variable absorption, extensive metabolism, uncertain tumor exposure, absence of a validated human dose, veterinary formulation variability, and reported severe hepatocellular injury substantially limit translation.</td>
</tr>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>